네이버 증권
SillaJen announced its own anti-cancer virus treatment, Pexavec, at ESMO2019.
The daily limit is set at the news of the announcement of the clinical first phase of pre-treatment by Pexabeck, a liver cancer treatment drug.
As the results of the complete extinction of the tumor in patients with liver-plastic colorectal cancer have been announced, shares of Shillazen seem to have risen on expectations of the company's growth.
Pexavec administration gives you anti-cancer immunity.
Quickly activating the immunity can cause a rapid cell response, which can lead to an anti-cancer effect.
Sillajen closed at 1,0550 won, up 29.61 percent from the previous day.
Along with Eichaelbi, there were some Zeak and Bio related stocks in the clinical expectations!
The daily limit is set at the news of the announcement of the clinical first phase of pre-treatment by Pexabeck, a liver cancer treatment drug.
As the results of the complete extinction of the tumor in patients with liver-plastic colorectal cancer have been announced, shares of Shillazen seem to have risen on expectations of the company's growth.
Pexavec administration gives you anti-cancer immunity.
Quickly activating the immunity can cause a rapid cell response, which can lead to an anti-cancer effect.
Sillajen closed at 1,0550 won, up 29.61 percent from the previous day.
Along with Eichaelbi, there were some Zeak and Bio related stocks in the clinical expectations!
HelixSmith, Medytox, Genexine, Avielbio, Celltrion Pharmaceutical, Celltrion Healthcare and Samsung BioLogics are strong.
